Albert David Limited

Equities

ALBERTDAVD

INE155C01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-26 am EDT 5-day change 1st Jan Change
1,191 INR +1.62% Intraday chart for Albert David Limited +6.05% +22.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Albert David Limited Announces Board Retirement CI
Albert David Limited Announces Management Changes CI
Albert David Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Albert David Limited Announces Resignation of A. B. Chakrabartty as Company Secretary and Compliance Officer Cum Legal Head of the Company CI
Albert David Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Albert David to Invest INR6 Million in Solar Power Company MT
Sunsure Solarpark Five Private Limited announced that it expects to receive INR 6.125 million in funding from Albert David Limited CI
Albert David Limited Approves Dividend for the Financial Year Ended March 31, 2023 CI
Albert David Limited Announces Board Changes CI
Albert David Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Albert David Limited Recommends Dividend for the Financial Year 2022-2023 CI
Albert David Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
CARE Upgrades Rating on Albert David's Long-term Bank Financing; Outlook Stable MT
Albert David Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Albert David Names New CEO MT
Albert David Limited Appoints Mr. A B Chakrabartty as the Company Secretary & Compliance Officer Cum Legal Head of the Company CI
Albert David Limited Appoints Mr. Umesh Kunte as the Chief Executive Officer, Effective on February 06, 2023 CI
Albert David Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Albert David Limited Announces Reconstitution of Committees of the Board of Directors CI
Albert David CEO Resigns MT
Albert David Limited Announces Resignation of Tarminder Singh Parmar as Managing Director and CEO, Effective December 8, 2022 CI
Albert David Limited Announces Management Changes CI
Albert David Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Albert David Limited Approves the Appointment of Anand Vardhan Kothari as an Additional Director (Non-Executive Non-Independent) CI
Albert David Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
Chart Albert David Limited
More charts
Albert David Limited is engaged in manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. The Company offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. It has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.
More about the company
  1. Stock Market
  2. Equities
  3. ALBERTDAVD Stock
  4. News Albert David Limited
  5. Albert David to Invest INR6 Million in Solar Power Company